Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.

Clinical and translational science·2026
Same author

Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses.

Circulation. Cardiovascular interventions·2026
Same author

The Aging Kidney and Acute Kidney Injury.

Journal of the American Society of Nephrology : JASN·2026
Same author

Diagnostic Performance of Non-Hyperemic Pressure Ratios Versus Fractional Flow Reserve Stratified by Coronary Artery: A Systematic Review and Meta-Analysis of Individual Patient Data.

Journal of the American Heart Association·2026
Same author

NAD + -Boosting Ameliorates Heme Protein-Mediated Acute Kidney Injury.

Kidney360·2025
Same author

Echocardiographic Correlates of Hyponatremia in Critically Ill Patients With Heart Failure.

International journal of heart failure·2025

相关实验视频

Updated: Jun 27, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

791

因弗利克西马布限制了心肌梗塞中的损伤.

Christopher Livia1,2, Sara Inglis1,3, Ruben Crespo-Diaz1,3,4

  • 1Van Cleve Cardiac Regenerative Medicine Program Mayo Clinic Rochester MN USA.

Journal of the American Heart Association
|May 3, 2024
PubMed
概括

在心肌梗塞 (MI) 中使用因弗利克西马布向瘤坏死因子-α 减少了炎症,改善了心脏功能. 这种免疫调节策略保留了收缩性,并限制了心脏病发作后的不良改造.

关键词:
抑制TNFα的抑制作用免疫调节的免疫调节这就是Infliximab.心肌梗塞的心脏病发作猪模型的猪模型

更多相关视频

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

27.7K
Left Coronary Artery Ligation: A Surgical Murine Model of Myocardial Infarction
05:48

Left Coronary Artery Ligation: A Surgical Murine Model of Myocardial Infarction

Published on: August 9, 2022

4.3K

相关实验视频

Last Updated: Jun 27, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

791
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

27.7K
Left Coronary Artery Ligation: A Surgical Murine Model of Myocardial Infarction
05:48

Left Coronary Artery Ligation: A Surgical Murine Model of Myocardial Infarction

Published on: August 9, 2022

4.3K

科学领域:

  • 心血管医学 心血管医学
  • 免疫学 免疫学 免疫学
  • 再生医学是一种再生医学.

背景情况:

  • 缺血性心肌损伤引发炎症反应和不良的心脏重塑.
  • 在炎症级联中识别分子标对于治疗干预至关重要.
  • 瘤坏死因子-α (TNF-α) 信号传递与心肌梗塞 (MI) 的进展有关.

研究的目的:

  • 研究一种针对缺血性心肌损伤炎症反应的治疗方法.
  • 评估TNF-α信号传递在ST段升高心肌梗塞 (STEMI) 患者中的作用.
  • 评估TNF-α抑制剂Infliximab在缓解心脏病发作后心脏损伤方面的疗效.

主要方法:

  • 基于阵列的冠状动脉血栓蛋白质组分析从STEMI患者吸收.
  • 根据临床结果将患者分为脆弱和弹性群体进行分层.
  • 在猪MI模型中,输入内注射Infliximab在再注射时.
  • 量化M2巨细胞,I型热素水平和细胞因子概况.
  • 在MI后4周评估左心室喷射率和痕大小.

主要成果:

  • 网络分析发现TNF-α信号传递是临床结果较差的患者的关键因素.
  • 在猪模型中,因弗利克西马布治疗增加了心肌边界区域的前再生M2巨细胞.
  • 输注Infliximab导致了较低的托罗邦素I水平和损伤修饰细胞因子的上调调节.
  • 在4周后,因弗力西马布治疗显著改善了左心室喷射率,并减少了心脏痕大小.

结论:

  • 在STEMI患者中冠状动脉血栓吸收的剖析突出了TNF-α与受伤风险的关联.
  • 以infliximab为媒介的免疫调节为改变MI诱导的炎症反应提供了一个可行的治疗策略.
  • 这种方法保持了心脏收缩性,并限制了心肌梗塞后不良的结构重塑.